Could New Long-Term Data Support Capricor’s Duchenne Therapy?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy.
Capricor Therapeutics Inc. (CAPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.36 | 2,798,507 | $14,999,997.52 | 7,090,351 | 2024-09-20 | Filing | |
| $2.75 | 410 | $1,127.50 | 31,536 | 2023-10-12 | Filing | |
| $2.83 | 10,000 | $28,300.00 | 26,856 | 2023-10-10 | Filing | |
| $2.82 | 5,083 | $14,334.06 | 31,126 | 2023-10-09 | Filing | |
| $2.84 | 5,000 | $14,200.00 | 5,000 | 2023-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.38 | 24,100 | $732,158.00 | 30,547 | 2026-06-25 | Filing | |
| $30.38 | 24,100 | $732,158.00 | 11,223 | 2026-06-25 | Filing | |
| $30.00 | 400 | $12,000.00 | 30,547 | 2026-06-24 | Filing | |
| $30.00 | 500 | $15,000.00 | 30,547 | 2026-06-22 | Filing | |
| $30.00 | 400 | $12,000.00 | 11,223 | 2026-06-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,137,681 | $10,775,852 | 0% | |
| 2. | 360,665 | $3,415,498 | 0% | |
| 3. | 288,000 | $2,727,360 | 0% | |
| 4. | 275,957 | $2,613,312 | 0% | |
| 5. | 245,400 | $2,323,938 | 0% |
News See All
A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path
On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy...
Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?
Capricor Therapeutics, Inc.
10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now
In this article, we will discuss the 10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript May 12, 2026Capricor Therapeutics, Inc. misses on earnings expectations.
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts.
13 Best Hot Stocks to Buy According to Analysts
In this article, we will discuss the 13 Best Hot Stocks to Buy According to Analysts.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript March 12, 2026 Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2025 Earnings Call Transcript November 10, 2025Capricor Therapeutics, Inc. reports earnings inline with expectations.
Hedge Fund Resource Center